MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

This study is testing whether using a sensitive blood test (called MRD — measurable residual disease) to guide treatment decisions after initial therapy with almonertinib (a targeted drug) can improve outcomes for people with unresectable stage III non-small cell lung cancer that carries a specific mutation called EGFR. **You may be eligible if:** - You are 18–70 years old - You have stage III non-small cell lung cancer that cannot be surgically removed - Your tumor has an EGFR mutation (specifically exon 19 deletion or L858R) - You are in generally good health (ECOG 0–1) with no signs of disease worsening recently **You may NOT be eligible if:** - You have previously had lung surgery, chemotherapy, immunotherapy, or targeted therapy for lung cancer - You have another active cancer - You have serious heart rhythm problems, severe lung scarring, or uncontrolled infections - You are pregnant or breastfeeding - You have a history of severe eye disease Talk to your doctor to see if this trial is right for you.